PTC Therapeutics is a pharmaceutical company focusing on the discovery, development, and commercialization of orally administered small-molecule drugs. They target genetic disorders, oncology, and infectious diseases. Founded in 1998 and based in South Plainfield, New Jersey, the company boasts a diverse and loyal workforce with 50% female and 59.7% ethnic minority employees, who tend to stay with the company for an average of 5.3 years.
The company's major product is Ataluren, an investigational drug for the treatment of cystic fibrosis and Duchenne muscular dystrophy caused by nonsense mutations. PTC Therapeutics also provides PTC299, an anti-angiogenesis drug aimed at treating metastatic breast cancer, multiple tumors, and neurofibromatosis. Under the leadership of CEO Stuart W. Peltz Ph.D., Ptc Therapeutics maintains competitive employee salaries within the industry and continues to grow its portfolio of innovative treatments.
